| Prev Close | 0.27 |
| Open | 0.27 |
| Day Low/High | 0.27 / 0.29 |
| 52 Wk Low/High | 0.24 / 1.40 |
| Volume | 69.43K |
| Avg Volume | 361.10K |
| Exchange | OTC |
| Shares Outstanding | 117.98M |
| Market Cap | 34.19M |
| EPS | -0.18 |
| Div & Yield | N.A. (N.A) |
Latest News
Interesting ONCY Call Options For May 17th
Investors in Oncolytics Biotech Inc saw new options become available this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ONCY options chain for the new May 17th contracts and identified the following call contract of particular interest.
3 Stocks Under $10 Making Big Moves
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
3 Biotech Stocks Under $10 to Trade for Breakouts
These under-$10 biotech stocks are within range of triggering breakout trades.
5 Stocks Under $10 Set to Soar
These under-$10 stocks look ready to trade higher from current levels.
Consider Buy Rated Stocks Under Five Bucks as Stocking Stuffers
Advanced Micro and Alaska Communications lead nine stocks trading under $5 as speculative stocking stuffers for possible positive returns in 2014.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Launches Investigation Of ONCOLYTICS BIOTECH INC. For Possible Violations Of Federal Securities Laws
Levi & Korsinsky is investigating Oncolytics Biotech Inc. (“Oncolytics” or the “Company”) (NasdaqCM: ONCY) for possible violations of federal securities laws.
Oncolytics Biotech Shades Truth On Failed Cancer Study
There are too many red flags to count in the way Oncolytics Biotech spins results from the Reolysin head and neck cancer study.
Biotech Stock Mailbag: Ariad, NewLink, Zogenix, 5 Falling Stocks For Rest of '13
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Oncolytics Pumps Stock With Worsening Lung Cancer Drug Data
Oncolytics claims positive Reolysin results, fails to mention falling response rates.
Biotech Stock Mailbag: MannKind, Ariad, Oncolytics Biotech
Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.
Biotech Stock Mailbag: Ziopharm, Oncolytics, Sarepta
Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.
Why Expect More Price Swings From These 4 Biotechs
Crish Lau, Kapitall Contributor  Companies in the biotechnology space are often trade like speculative investments. Speculation for FDA approvals may [...]
Stocks Finish Higher Ahead of Fed Decision
The major U.S. equity averages edge up ahead of the central bank's policy decision on Thursday. Apple shares enjoy a boost from the debut of the iPhone 5.
Biotech Stock Mailbag: Oncolytics, Sarepta, Delcath, Peregrine
Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.
8 Stocks Under $10 Moving Higher
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
BIO CEO Conference Live Blog
TheStreet's biotech columnist, Adam Feuerstein, will be providing live coverage from the BIO CEO biotech investor conference.
Amgen Makes Bet on Viral Skin Cancer Killer
Amgen's purchases BioVex to get into the cancer immunotherapy game.
Biotech's Brighter Corners
Speculative opportunities abound in the small- and mid-cap universe, but only for aggressive market players.
Increased Risk of News-Driven Shock Gaps
Every quarter brings a few surprises, and this one could be open to more heading into the November elections.
Columbia Laboratories, Cardionet: Early Volume Plays
Several stocks trading near $5, including Columbia Laboratories, were poised to move on above-average volume Tuesday.
Poniard, Netlist: Early Volume Plays
Several stocks trading under $5 were poised to move on above-average volume during Wednesday's session.
Tuesday's Small-Cap Winners & Losers
Globalstar falls due to concerns over deterioration of its satellites.
Weekend Reading: Markets Seem Frozen With Fear
Focusing on terror threats, markets have been locked in an 8% range for 128 consecutive sessions.
